Natural Biogenex completes its maiden fund-raise of Rs 18.75 Cr
The proceeds from this fund-raise will be deployed in financing the project requirements of the API business
The proceeds from this fund-raise will be deployed in financing the project requirements of the API business
Acquisition expands Merck’s growing hematology portfolio
Omicron BA.5 continues to be the most prevalent sublineage in the United States (nearly 30% of cases) at the time of publication of the data
The product is expected to be launched by Q4 FY23.
The show will be a part of the India Pharma Week, a marquee celebration catering to every need of the pharma community attendees
Within the API segment, ~20% of the revenues came from the domestic market and ~80% from the exports market
The company registered with REACH Certificate for Ethyl Acetate with a tonnage band of more than 1000 TPA
Formulation revenue decreased by 7.6% YoY to Rs. 4,770 crore whereas in Q2 FY23, API business posted a growth of 24.2% YoY with revenue of Rs. 969.4 crore
First and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe
Subscribe To Our Newsletter & Stay Updated